Objective Myeloid-related protein-14 (MRP14) and its binding partner MRP8 play an essential role in innate immune function and have been implicated in a variety of inflammatory diseases. However, the role of MRP14 in obesity-induced inflammation and insulin resistance is not well defined. This study investigated the role of MRP14 in macrophage-mediated adipose tissue inflammation and obesity-induced insulin resistance.
Introduction
Myeloid-related protein-14 (MRP14, S100A9) and its binding partner MRP8 (S100A8) are members of the S100 calcium-binding family of proteins, which are predominantly expressed in, and released from, myeloid cells. MRP8/14 complex, also called calprotectin, is capable of sequestering transition metals [1] . MRP14 and MRP8 are expressed in phagocytic myeloid cells, such as neutrophils, monocytes, dendritic cells, activated macrophages (but not nonactivated macrophages), and platelets [2] . The expression of MRP8/14 is upregulated by oxidative stress, specific cytokines, and growth factors [3] . MRP14 is required for the stability of the MRP8 protein, as shown by Mrp14 −/− mice not expressing MRP8 protein, despite the presence of MRP8 mRNA [4] .
In addition to the metal sequestration function, MRP8/14 can also be released from the cells and serves as an alarmin to activate the immune system during inflammation [5, 6] . MRP8/14, an endogenous agonist of TLR4, plays an important role in sterile inflammation by activating TLR4/ NF-κB signaling [5, [7] [8] [9] . A receptor for advanced glycation end products (RAGE) has also been identified as a receptor for MRP8/14, promoting inflammation and cell growth in an NF-κB-dependent manner [10, 11] . Croce et al. reported that MRP14 deficiency in ApoE −/− mice showed a significant attenuation in atherosclerotic lesions and vasculitis. There was less macrophage accumulation in the plaque and lower levels of macrophage cytokines, such as TNFα, IL-1β, MCP-1, and IL-12 in Mrp14 −/− ApoE −/− mice [12] . Increasing evidence suggests a role for macrophage MRP8/14 in obesity and diabetes. The levels of MRP8/14 in circulation and in visceral adipose tissue were significantly increased in obese patients and positively correlated with monocyte/macrophage markers, such as macrophagespecific antigen CD68 (CD68), monocyte chemotactic protein 1 (MCP-1), and CD11b [13] . Mortensen et al. also reported that the plasma level of MRP8 was positively associated with the degree of obesity, as indicated by body mass index (BMI) [14] . Later studies indicate that adipose MRP8/14 induces bone marrow myelopoiesis. This could be achieved either directly through activating RAGE on myeloid progenitor cells or indirectly via stimulating the IL-1 receptor on myeloid progenitor cells by inducing IL-1β release from adipose tissue macrophages [15, 16] . Although hyperglycemia has been shown to induce MRP8/14 and myelopoiesis [16] , it is not clear if MRP8/14 affects glucose metabolism and insulin resistance. In this study, we provide direct evidence showing that MRP14 is involved in obesityinduced inflammation and insulin resistance. MRP14 expression, in insulin target organs such as the liver and adipose tissue, was increased in obese mice. Extracellular MRP8/14 upregulates the production of multiple chemokines, such as CCL-2, CCL5, and CXCL9 from macrophage, leading to an enhanced recruitment of T cells. Mrp14-deficient mice (Mrp14 −/− ) lacking MRP8/14 complexes had a significantly increased insulin sensitivity, accompanied with reduced T-cell infiltration.
Materials and methods

Reagents
Recombinant mouse MRP8/14 heterodimer was purchased from R&D Systems (Minneapolis, MN). Standard LPS 0111: B4 (from E. coli) was purchased from InvivoGen (San Diego, CA). Anti-phospho-NF-kB p65 (Ser536), β-Actin (8H10D10) mouse antibody, and α/β-Tubulin antibody were obtained from Cell Signaling Technology (Danvers, MA 
Animals
Mrp14 −/− mice were generated in the laboratory of Nancy
Hogg [17] . Tlr4Lps-d C3H mice were purchased from Jackson Laboratory. Eight-week-old male Mrp14 −/− and wild-type (WT) littermate controls were randomized to either a normal chow diet (ND) or a high-fat diet (HFD), with 42% calories from fat (Harlan TD.88137), for 12 weeks. The mice were maintained in the animal facility at the Case Western Reserve University. All mice had a congenic C57BL/6 background, and all procedures of this study were approved by the Institutional Animal Care and Use Committees at the Case Western Reserve University.
Intraperitoneal glucose tolerance test and insulin tolerance test
For intraperitoneal glucose tolerance test (IPGTT), baseline blood glucose and body weights were measured after overnight fasting with free access to drinking water. Mice were i.p. injected with 2.0 g/kg body weight D-glucose and blood glucose levels were measured at 30, 60, 90, and 120 min post injection using a Bayer Contour® glucometer. For insulin tolerance test (IPITT), baseline blood glucose and body weights were measured after 4 h of fasting with free access to drinking water. Mice were i.p. injected with 0.75 U/kg body weight insulin and blood glucose levels were measured at 30, 60, 90, and 120 min post injection using a Bayer Contour® glucometer.
Adipose tissue and liver immunofluorescence
Epididymal fat and liver tissue from WT and Mrp14 −/− mice (ND-fed or HFD-fed) were fixed in 10% neutral buffered formalin and embedded in paraffin. Paraffinembedded tissue sections (8 μm) were used for detection of MRP14 by immunohistochemistry. Sections were blocked in 1% BSA for 1 h after incubation in 1× RetrieveAll Antigen Unmasking Solution (Covance, Vienna, VA). MRP14 primary antibodies were diluted in blocking solution (10 μg/ml) and applied for at least 1 h at room temperature. Sections were then incubated with Texas Redlabeled anti-goat secondary antibody (10 μg/ml) diluted in 1% BSA in the dark for 1 h at room temperature. Resident macrophages were labeled with a FITC-conjugated rat antimouse CD11b antibody. Nuclei were stained with DAPI. Images were captured using a Leica microscope (DM2500) with a RETIGA EXi Fast 1394 camera (QIMAGING, Surrey, BC, Canada).
Bone marrow-derived macrophage induction and stimulation
Bone marrow cells from 8-to-12-week-old male WT or Mrp14 −/− mice were cultured in RPMI-1640 supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 25 ng/mL M-CSF for 7 days to induce bone marrowderived macrophages (BMDMs Table 1 . Fold changes of mRNA levels were determined using the ΔΔCt method and normalized to β-actin.
Transwell® assays
Transwell® assays were performed in Corning® Transwell® 24-well plate (6.5-mm diameter, 5 µM pore). To assess the chemotactic effects of WT and Mrp14 −/− BMDMs on T cells, immature BMDMs (without LPS induction), and mature BMDMs (1 µg/mL LPS overnight treatment) were washed with 1× PBS three times and incubated in a fresh serum-free medium. After 24 h, the cell supernatant was collected for Transwell® assays. The splenocytes from WT mice were placed in the upper chamber (100-µL suspension) and the lower chamber was filled with 600-µL supernatants collected from BMDMs with indicated treatments. The Transwell® plates were then incubated in a 37°C CO 2 incubator for 5 h. Cells were collected from both the upper and the lower chambers for cell counting and flow-cytometric analysis after staining with cell population markers. The number of cells was counted three times for each sample, and mean values and SD around the mean were calculated.
Flow cytometry
Cells were gated based on viability (Life Technologies live/ dead). Mouse antibodies (CD4, clone GK1.5; CD11b, clone M1/70; CD19, clone1D3; CD8, clone SK1; CD3 clone 2C11) were used in flow cytometry. Samples were collected on a Flowsight® imaging flow cytometer (Millipore) and analyzed with IDEAS software. iBIDI® 3D chemotaxis assays and migration in collagen I gels
Splenocytes isolated from WT mice were suspended with serum-free RPMI medium. Cell concentration was 18 × 10 6 / ml using ibidi's μ-Slide Chemotaxis 3D to reach a final concentration of 3 × 10 6 /ml. For collagen preparation, 50 µL of spleen leukocytes (18 × 106/ml) were carefully mixed with 90 µL of rat tail type I collagen (5 mg/ml), 4 µL of NaHCO 3 (stock 7.5%), 50 µL of 1× DMEM, 20 µL of 10× DMEM, and 5 µL of 1 M NaOH. All solutions were previously placed on ice for 10 min. The final collagen I concentration in the gel was 1.5 mg/ml. Six microliters of gel mix was then loaded in a μ-Slide Chemotaxis 3D and incubated at 37°C (5% CO 2 ) for 30 min to allow collagen polymerization. After incubation, the right chamber (chemoattractant-free side) was filled with 65 µl of chemoattractant-free medium and the left chamber (chemoattractant side) was filled with 65 µl of culture supernatant from BMDMs with indicated treatments. CCL19 (100 ng/mL) was used as a positive control. Time-lapse videos/images were recorded on a microscopy using a ×10 objective. Cell migration was monitored for 12 h. At least 30 cells over the whole period were tracked.
Chemokine production
For chemokine secretion, BMDMs with indicated treatments were washed for three rinses with 1× PBS and cultured in fresh RPMI-1640 medium containing M-CSF (25 ng/mL). After 24 h, supernatants were harvested after centrifugation. CCL5 and CXCL9 levels in supernatants were measured using ELISA kits, as instructed by the manufacturers.
Immunoprecipitation
To deplete extracellular MRP8/14 in BMDM supernatants, Protein G magnetic beads (50 µl) were incubated with 5 µg of anti-MRP14 antibody in 200 µl of PBS for 10 min. After washes, protein G beads conjugated with anti-MRP14 Ab were incubated with supernatants with rotation for 45 min at room temperature to allow extracellular MRP8/14 to bind to the beads-Ab complex. The supernatants were then transferred to a clean tube for further treatment. The beads-Ab-Ag complex was washed three times using 200 µl of washing buffer and then eluted in 20 µl of elution buffer, followed by western blot analysis.
Glycolysis rate and mitochondrial respiration rate
For the measurements of glycolysis rate and mitochondrial respiration rate, BMDMs were plated at the concentration of 150,000/well and accessed using the XF Glycolysis Stress Test Kit and the XF Cell Mito Stress Test Kit, according to the manufacturer's instructions. ECAR and OCR were measured using the Seahorse XF24 Extracellular Flux Analyzer (Seahorse Bioscience) as described previously [18] . The data were automatically calculated by Seahorse XF Glycolysis Stress Test and Cell Mito Stress Test Report Generator.
Cell proliferation
BMDMs were treated with or without recombinant mouse MRP8/14 heterodimer protein (3 µg/ml) and harvested for the detection of cell proliferation using Click-iT™ EdU Alexa Fluor™ 647 Flow Cytometry Assay Kit (ThermoFisher Scientific, Waltham, MA) as instructed. Cells were analyzed on a Flowsight® Imaging Flow Cytometer.
Statistical analysis
All data are presented as mean ± SEM. P values of <0.05 were considered statistically significant. The statistical analysis of Student t test or one-way or two-way ANOVA and Bonferroni post hoc test where appropriate, was completed using GraphPad Prism 5.
Results
The expression of MRP14 increased in obesity
To examine the potential involvement of MRP14 in obesityinduced diabetes, we evaluated the expression of MRP14 in WT mice on normal chow diet (ND) vs. high-fat diet (HFD) for 12 weeks. As depicted in Fig. 1a , HFD feeding increased adipocyte size and induced crown-like structures with massive macrophage infiltration in the visceral adipose tissue. There was an increased expression of MRP14 in HFD-fed mice compared with that of the ND group, with MRP14 mainly expressed on CD11b-expressing macrophages (Fig. 1a) . Similarly, the HFD increased the expression of MRP14 in the liver (Fig. 1b) .
Loss of MRP14 improves insulin sensitivity
To test the role of MRP8/14 in the development of insulin sensitivity, WT and Mrp14 −/− mice were fed with a HFD or ND for 12 weeks. HFD feeding significantly increased body weight and fasting blood glucose in both WT and Mrp14 −/− mice. However, there were no significant differences in body weight, tissue weight (epididymal fat, inguinal fat, liver, and soleus muscle), fasting blood glucose, or serum insulin between WT and Mrp14 −/− mice ( (Fig. 1f, h ).
The areas under the curve of the IPGTT and ITT tests were also at similar levels between ND-fed and HFD-fed Mrp14 −/− mice, although there was a trend to increase by 12 weeks of HFD feeding (Fig. 1g, i ). In addition, the expressions of Cd4, Cd8, Il1b, Tnfa, Ccl2, and Cxcl9 were reduced, while M2 marker Fizz1 was increased in the adipose tissue of HFD-fed Mrp14 −/− mice (Fig. 1j) .
Effects of MRP14 on inflammatory gene expression in macrophage
Differentiation of macrophages has been suggested to alter expression of MRP8/14, raising the possibility that this may differentially affect function and expression of other cytokines. While no significant difference in Tnfa expression was observed between WT and Mrp14 −/− undifferentiated bone marrow cells (Fig. 2a) , the expressions of Il1b (1 ± 0.23 vs. 0.47 ± 0.15 for WT vs. Mrp14 −/− , p < 0.001) and
Il6 (1 ± 0.27 vs. 0.39 ± 0.13 for WT vs. Mrp14 −/− , p < 0.001) were reduced significantly in Mrp14 −/− mice (Fig.   2b, c) . Differentiated naive macrophages (untreated BMDMs) showed the same results ( Fig. 2d-f ). In contrast, mature (LPS-treated) Mrp14 −/− macrophages had reduced expressions of Tnfa and Il1b, but not Il6 (Fig. 2d-f ). Since the production of IL-1β is regulated by NLRP3 inflammasome, we next examined the expression of NLRP3 and activation of caspase-1. Mrp14 −/− BMDMs had a lower level of Nlrp3 mRNA expression, while treatment with exogenous MRP8/14 complex increased Nlrp3 expression and there were no differences in Nlrp3 expression between WT and Mrp14 −/− macrophages after MRP8/14 treatment (Fig. 2g) . Consistent with this, protein levels of NLRP3 were also reduced in Mrp14 −/− macrophages, compared with WT (Fig. 2h) . The active form of caspase-1 was increased after MRP8/14 treatment in both WT and Mrp14 −/− macrophages, while LPS treatment increased the activation of caspase-1 in WT but not Mrp14 −/− macrophages (Fig. 2i, j) . These data suggested that inflammatory stimuli, such as LPS, may induce activation of caspase-1 through the secretion of extracellular MRP14. To confirm this hypothesis, an anti-MRP14 antibody was used to pull down MRP14 in the cell culture supernatant from untreated and LPS-treated WT macrophages. MRP14 was then precipitated from the supernatant and its levels were quantified by western blot. The results indicated that LPS treatment significantly enhanced the release of MRP14 (Fig. 2k) . We next examined the effects of MRP14 on macrophage proliferation. WT and Mrp14 −/− macrophages were treated with or without recombinant mouse MRP8/14 protein, and cell proliferation of BMDMs was evaluated by Click-iT™ EdU Alexa Fluor™ 647 Flow Cytometry Assay. There was no significant difference in proliferation between WT and Mrp14 −/− macrophages ( Supplementary Fig. 2a-c) . Similarly, treatment with extracellular MRP8/14 did not affect macrophage proliferation ( Supplementary Fig. 2a-c) . In consistency, there was also no significant difference in the expression of the macrophage marker CD11b in the adipose tissue between WT and Mrp14 −/− mice ( Supplementary   Fig. 2d ). These data indicate that MRP14 does not directly regulate macrophage proliferation. To examine a role for Mrp14 −/− macrophages in regulation of macrophage metabolism, we evaluated cellular bioenergetics using a Seahorse XF24 Analyzer. There were no significant differences in glycolic capacity and mitochondrial respiration between WT and Mrp14 −/− macrophages ( Supplementary   Fig. 3a-e) .
Effects of MRP14 on chemokine production from macrophage
As depicted in Fig. 3a (Fig. 3f-j) . Consistent with this, both naive and mature BMDMs showed a similar expression pattern of Ccl2, Ccl5, and Cxcl9 (Fig. 3k-m) . ELISA assays confirmed the upregulation of CCL5 and CXCL9 in the culture supernatant (Fig. 3n, o) . Since LPS treatment induces MRP14 release (Fig. 3k) , we wondered if MRP14 within the cell culture supernatant mediates the upregulation of these chemokines. To test this hypothesis, WT and Mrp14 −/− macrophages were treated with or without culture supernatants from LPS-treated WT macrophages. Ccl5 and Cxcl9 mRNA expressions were then Fig. 1 The MRP14 expression increased in obesity and insulin sensitivity in MRP14-deficient mice. Epididymal fat pad (a) and liver (b) tissues were isolated from wild-type (WT) C57BL/6 mice on normal chow diet (ND) or high-fat diet (HFD) and used for detection of MRP14 by immunofluorescence staining (mean ± SD, n = 8 per group). Resident macrophages were labeled in vivo using an FITCconjugated rat anti-mouse CD11b antibody. Nuclei were stained with DAPI. WT mice and Mrp14 −/− mice were fed with ND or HFD for 12 weeks. Body weight (c), tissue weight (d), fasting blood glucose (e), and responses to IPGTT (f blood glucose level before and after glucose challenge; g area under the curve) or IPITT (h blood glucose level before and after insulin challenge; i area under the curve) were measured. eWAT, epididymal white adipose tissue; iWAT, inguinal white adipose tissue. *p < 0.05 compared with WT; # p < 0.05 compared with ND detected using real-time PCR. Supernatants from mature WT macrophages induced higher expressions of Ccl5 and Cxcl9 from both WT and Mrp14 −/− cells, compared with those without supernatant treatment. More importantly, the differences between WT and Mrp14 −/− were either diminished (Cxcl9) or reduced (Ccl5) after treatment of supernatants from LPS-treated macrophages which contained a significant amount of MRP14 (Fig. 4a, b) . Therefore, a supernatant collected from mature macrophages was used for the following depletion experiments. To further confirm if the effect of chemokine upregulation is mediated by MRP14, MRP14 was depleted from the supernatant using an anti-MRP14 antibody conjugated with Protein G magnetic beads. As shown in Fig. 4c, d , the ability of WT mature macrophage-conditioned media to stimulate Ccl5 and Cxcl9 production was significantly reduced after MRP14 depletion. In contrast, MRP14 depletion did not affect the production of Ccl5 and Cxcl9 from Mrp14 −/− supernatant-treated cells (Fig. 4e, f) . These results suggest that MRP14 within the macrophages (especially mature (Fig. 5a ). The migrated cells were then collected from the bottom wells of the Transwell® plate and used for flow-cytometric analysis of cell components ( Fig. 5b-h) . A supernatant collected from mature Mrp14 −/− macrophages attracted less T cells (including CD4 + and CD8 + T cells) and macrophages, but not B cells (Fig. 5c-h ). Ibidi® 3D chemotaxis assay showed similar results that a supernatant from Mrp14 −/− macrophages had a reduced ability to attract splenocytes ( Fig. 5i-k) . These results indicate that extracellular MRP14 may play a role in chemokine production and inflammatory cell recruitment. To exclude the direct effects of extracellular MRP8/14 on cell migration, MRP14 was depleted from the WT macrophage culture −/− bone marrowderived macrophages (BMDMs) were stimulated with recombinant MRP8/14 heterodimer (3 μg/mL) for 16 h and the mRNA expressions of Ccl2 (f), Ccl5 (g), Cxcl9 (h), Cxcl10 (i), and Ccl22 (j) were detected by real-time PCR. k-m mRNA expressions of Ccl2 (k), Ccl5 (l), and Cxcl9 (m) were detected in untreated (UT) or LPS-treated WT or Mrp14 −/− BMDMs. n, o Culture supernatant of WT or Mrp14 −/− BMDMs was used for the ELISA detection of CCL5 (n) and CXCL9 (o) production. *p < 0.05 compared with WT; # p < 0.05 compared with UT MRP14 enhances the ability of macrophage to recruit T cells and promotes obesity-induced insulin. . .supernatant before the migration assay. As depicted in Fig. 5l , depletion of MRP14 did not affect the ability of WT supernatants to attract splenocytes, suggesting that the migration was induced by MRP14-mediated chemokine production rather than MRP14 itself. Consistent with these in vitro observations, high-fat diet feeding increased T-cell infiltration in the liver of WT mice, but not in the liver of Mrp14 −/− mice (Fig. 5m) .
MRP14 stimulates CCL5 and CXCL9 production through activating TLR4/NF-κB pathway Extracellular MRP8/14 has been shown to activate NFκB by binding to TLR4 [19] . We therefore tested to see if MRP14-induced chemokine production depends on TLR4/NF-κB signaling. MRP8/14 treatment induced NF-κB activation (Fig. 6a) . LPS-stimulated WT macrophages had a higher level of NF-κB activation, compared with Mrp14 −/− macrophages, while depletion of extracellular MRP14 by antibody-mediated pulldown abolished this difference (Fig. 6b, c) . Furthermore, the upregulation of Ccl5 and Cxcl9 by exogenous MRP8/14 was abrogated by the proteasome inhibitor MG132, which blocks activation of NF-κB (Fig. 6d) . MRP8/14 was unable to enhance the expression of Ccl5 and Cxcl9 in C3H mice with loss-offunction mutation of TLR4 (Fig. 6e) . These results indicate that MRP8/14-induced CCL5 and CXCL9 are dependent on TLR4/NF-κB activation.
Discussion
Our work suggests an important role of MRP8/14 in insulin resistance and postprandial glucose homeostasis in the absence of manifest changes in body weight or fasting glucose levels. In this study, we identified a new mechanism by which MRP14 plays a significant role in obesity-induced insulin resistance. MRP14 expression in the liver and adipose tissue was upregulated in obesity. MRP14 played an important role in regulation of expression of cytokines, such as IL-1β, through an inflammasome pathway. This required the participation of extracellular MRP14. MRP14 did not play a role in macrophage proliferation and consistent with this did not influence macrophage metabolism or bioenergetics. We uncovered an unexpected paracrine role for extracellular macrophage MRP14 in T-cell chemotaxis, likely via upregulation of chemokine synthesis in macrophages, such as CCL-2, CCL5, and CXCL9.
It was recently demonstrated that MRP8/14 broadly regulates both innate and acquired immune responses, which contribute to the development of chronic inflammatory diseases, including obesity [15] , cardiovascular disease + CD19 -macrophages (g), and CD19 + B cells (h) were calculated. i-k iBIDI® Chemotaxis Assays. The same culture supernatants described in Fig. 6a were also used for the iBIDI 3D Chemotaxis Assays representative plots (i), chemotaxis index (j), and migration velocity were shown. l Protein G magnetic beads conjugated with an anti-MRP14 antibody were used to deplete extracellular MRP8/14 in BMDM supernatants. Culture supernatants with or without depletion of MRP14 were used for Transwell® assay. Depletion of MRP14 did not affect the migration, suggesting that MRP14 does not directly induce cell migration. m Expression of T-cell marker Cd3e in the liver tissues of WT or Mrp14 −/− mice was shown. *p < 0.05 compared with WT; # p < 0.05 compared with UT [20] , and Alzheimer's disease [21] . However, the role of MRP14 in obesity-induced inflammation and insulin resistance is not well defined. Our results provided direct evidence showing that unlike WT mice, Mrp14 −/− mice were resistant to HFD-induced insulin resistance, despite having similar levels of obesity. Deficiency of MRP14 improved responses to glucose tolerance test and insulin tolerance test in both ND-and HFD-fed mice. Interestingly, the serum insulin level in Mrp14 −/− mice was similar as that in WT mice. These data suggest that Mrp14 −/− mice have enhanced insulin sensitivity. Obesity-associated inflammation is widely considered as one of the major factors provoking insulin resistance and triggering type 2 diabetes [22] . HFD feeding significantly enhanced insulin resistance in WT mice, while the responses to GTT and ITT were similar in ND-fed and HFD-fed Mrp14 −/− mice. In addition, serveral inflammatory markers were reduced in HFDfed Mrp14 −/− mice. These results suggest that loss of MRP14 may prevent obesity-induced inflammation and insulin resistance. Aging is also an important factor for chronic systemic inflammation [23] . We found that ND-fed Mrp14 −/− mice also displayed a better response to both GTT and ITT. Considering the fact that those mice were 5-months old after 12-week diet treatment, it is possible that the improvement in the insulin resistance was a result of reduced age-associated inflammation. However, the role of MRP14 in aging-related inflammation needs to be further investigated.
Macrophage accumulation in insulin target organs, such as the liver and visceral adipose tissue (VAT), plays a key role in obesity-associated inflammation and insulin resistance [22, 24] . The recruitment of monocytes into inflammatory sites and subsequent differentiation into macrophages is a major event underlying the chronic systemic inflammation [25] . Local macrophages are also able to proliferate and contribute to obesity-induced inflammation [26] . However, we did not observe a significant difference in adipose tissue macrophage number between WT and Mrp14 −/− mice. The deficiency of MRP14 also did not impair macrophage proliferation. Overexpression of MCP-1 produced by adipocytes could promote the recruitment of macrophages to adipose tissue, thereby enhancing VAT inflammation and impairing insulin sensitivity [27] . In addition, the release of the MRP8/14 complex has also been reported to contribute to vildagliptin-associated liver dysfunction [28] . In our study, we observed an upregulation of MRP14 in both adipose tissue and liver tissue from obese mice. The NLRP3 inflammasome and its downstream IL-1β are important mediators of obesity-induced inflammation and insulin resistance [29] . It is suggested that MRP8/14 is able to induce NRLP3 inflammasome activation and IL-1β production via binding to TLR4 [15] . In agreement with inflammasome plays a crucial role, given the fact that NLRP3-inflammasome inhibition has been suggested as an effective approach for the treatment of inflammatory diseases [30, 31] . Chemokine-mediated recruitment of inflammatory cells, including macrophages and T cells, is a critical step in obesity-induced inflammation and insulin resistance [32] [33] [34] . In this study, we found that extracellular MRP14 induced the expression of Ccl2, Ccl5, and Cxcl9 in macrophages. CCL-2, also known as monocyte chemoattractant protein 1 (MCP-1), is a key chemokine that regulates the migration of monocytes/macrophages in diet-induced obesity and insulin resistance [35, 36] . Both CCL5 (also called regulated on activation, normal T-cell expressed, and secreted, RANTES) and CXCL9 (also called monokine induced by gamma interferon, MIG) are important chemoattractants for T-cell recruitment [37] . Consistent with the chemokine expression profile, the supernatant from MRP14-deficient macrophages had less chemotactic activity for macrophages and T cells, but not B cells, in Transwell® assays.
MRP8/14 is actively released by macrophages in response to inflammatory stimuli and it serves as an innate alarmin to amplify immune response. Vogl et al. reported that LPS stimulation induces MRP8/14 secretion, which in turn augments LPS signaling through TLR4 [5] . In our study, we also found that LPS-treated macrophages secreted a significantly higher level of MRP14. In the following experiments, we confirmed that the extracellular MRP8/14 in turn acts on macrophages by activating the TLR4/NF-κB pathway to stimulate the production of CCL5 and CXCL9. Supernatants from WT, but not Mrp14 −/− macrophages, stimulated the expression of Ccl5 and Cxcl9. This effect was abolished by the depletion of MRP14 from the supernatant, loss-of-function mutation of TLR4, or via NF-κB inhibition. Studies have indicated that there was a tight link between metabolism and macrophage function [38] . Bustos and Sobrino reported for the first time, that the inhibition of cytokine production in macrophages impaired macrophage metabolism by inactivating the glycolytic enzymes PFK1 and PFK2 [39] . Our findings suggest that a deficiency of MRP14 did not change the macrophage mitochondrial respiration and glycolysis metabolic function. We also did not observe a direct effect of MRP14 on macrophage proliferation. This is consistent with the findings that MRP14 does not regulate myeloid cell development or differentiation in general [17] .
In summary, our data demonstrate that MRP8/14 regulates the ability of macrophages to recruit leukocytes under inflammatory conditions, which may provide an insight into the involvement of macrophage/T-cell inflammation in obesity-induced insulin resistance.
